Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.86 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.81 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359685 | 1.00 | PTGER4 (0.86) | PTGER4PTGER2MAPK8 | |
| SCHEMBL691838 | 0.92 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL19713765 | 0.92 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL5362948 | 0.91 | PTGER4 (0.81) | PTGER4PTGER2 | |
| SCHEMBL691746 | 0.91 | PTGER4 (0.88) | PTGER4PTGER2MAPK8 | |
| SCHEMBL5359123 | 0.91 | PTGER4 (0.88) | PTGER4PTGER2MAPK8 | |
| SCHEMBL4448244 | 0.91 | PTGER4 (1.00) | PTGER4PTGER2MAPK8 | |
| SCHEMBL19713730 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL120617 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL31049762 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | ASKAT INC. (JP) | 2017-09-07 | — | — | US | claimed |
| EP-1663979-B1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2013-10-09 | — | — | EP | claimed |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RAQUALIA PHARMA INC. (JP) | 2012-04-12 | — | — | US | claimed |
| EP-2422779-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RaQualia Pharma Inc (JP) | 2012-02-29 | — | — | EP | claimed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | claimed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | claimed |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | ARRYS THERAPEUTICS INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | ARRYS THERAPEUTICS INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | ASKAT INC. (JP) | 2023-12-12 | — | — | US | disclosed |
| EP-2976105-B1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC (JP) | 2023-01-04 | — | — | EP | disclosed |
| US-20220073510-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | ASKAT INC. (JP) | 2022-03-10 | — | — | US | disclosed |
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | ASKAT INC. (JP) | 2021-09-23 | — | — | US | disclosed |
| US-10973834-B2 | EP4 inhibitors and use thereof | Arrys Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RAQUALIA PHARMA INC. (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2422779-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RaQualia Pharma Inc (JP) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | PTGER4 1/4885PTGER2 5/4885MAPK8 2274/4885 |
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MAPK8 1753/4885 |
| US-20220073510-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MAPK8 1727/4885 |
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MAPK8 1727/4885 |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MAPK8 1790/4885 |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | PTGER4 13/4885PTGER2 11/4885MAPK8 3466/4885 |
| US-10973834-B2 | EP4 inhibitors and use thereof | PTGER4, EPB41, PTGER1 | PTGER4 1/4885PTGER2 5/4885MAPK8 2274/4885 |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | PTGER4 1/4885PTGER2 5/4885MAPK8 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.